Product Description
ECC0509 is a highly selective and peripherally distributed small molecule inhibitor of SSAO/VAP-1, elevated activity of which is associated with pathophysiology of human disorders including NASH and OA.
Mechanisms of Action: AOC3 Inhibitor, SSAO Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Eccogene
Company Location: Asia Pacific
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, United States
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Fatty Liver, Alcoholic|Hepatitis, Alcoholic|Liver Diseases, Alcoholic|Metabolic Dysfunction-Associated Steatohepatitis
Phase 1: Osteoarthritis
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT07873229 |
CYP1A2 Probe Substrate | P1 |
Not yet recruiting |
Hepatitis, Alcoholic|Fatty Liver, Alcoholic|Osteoarthritis|Metabolic Dysfunction-Associated Steatohepatitis |
2027-03-01 |
12% |
2026-10-15 |
|
NCT07288138 |
MASH | P2 |
Recruiting |
Metabolic Dysfunction-Associated Steatohepatitis|Hepatitis, Alcoholic|Liver Diseases, Alcoholic|Fatty Liver, Alcoholic |
2027-09-15 |
48% |
2026-04-23 |
Primary Completion Date|Primary Endpoints|Study Completion Date |